Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Key takeaways
- Ricardo Pillai Sun, June 14, 2026 at 3:55 AM GMT+7 3 min read HROW Is HROW a good stock to buy?
- The company operates across dry eye, ocular anesthesia, corticosteroids, and retinal biosimilars, with VEVYE, IHEEZO, and TRIESENCE driving momentum alongside launches BYQLOVI and biosimilars BYOOVIZ and OPUVIZ.
- Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Is Harrow, Inc. (HROW) A Good Stock To Buy Now? Ricardo Pillai Sun, June 14, 2026 at 3:55 AM GMT+7 3 min read HROW Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on Top Secret Stocks’s Substack by Simon. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc. s share was trading at $33.10 as of June 8th. HROW’s trailing and forward P/E were 9.64 and 232.56 respectively according to Yahoo Finance.
Harrow Inc (HROW) is a rapidly evolving ophthalmic pharmaceutical platform that has transformed from a niche compounding pharmacy into one of North America’s leading branded eye care players, positioned as a structurally undervalued mid-cap growth story. The company operates across dry eye, ocular anesthesia, corticosteroids, and retinal biosimilars, with VEVYE, IHEEZO, and TRIESENCE driving momentum alongside launches BYQLOVI and biosimilars BYOOVIZ and OPUVIZ.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich